Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors.
10.3779/j.issn.1009-3419.2019.10.06
- Author:
Xiaoyan SI
1
;
Chunxia HE
2
;
Li ZHANG
3
;
Xiaowei LIU
4
;
Yue LI
5
;
Hanping WANG
1
;
Xiaoxiao GUO
6
;
Jiaxin ZHOU
7
;
Lian DUAN
8
;
Li ZHANG
1
Author Information
1. Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Beijing 100730, China.
2. Department of Dermatology, Peking Union Medical College Hospital, Beijing 100730, China.
3. Department of Clinical Laboratory, Peking Union Medical College Hospital, Beijing 100730, China.
4. Department of Ophthalmology, Peking Union Medical College Hospital, Beijing 100730, China.
5. Department of Gastroenterology, Peking Union Medical College Hospital, Beijing 100730, China.
6. Department of Cardiology, Peking Union Medical College Hospital, Beijing 100730, China.
7. Department of Rheumatology, Peking Union Medical College Hospital, Beijing 100730, China.
8. Department of Endocrinology, Peking Union Medical College Hospital, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Dermatologic toxicities;
Immune checkpoint inhibitor;
Immunotherapy-related toxicities
- From:
Chinese Journal of Lung Cancer
2019;22(10):639-644
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic AEs, including Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare. In this review, we summarized guidelines of management of immunotherapy-related toxicities and case reports, and proposed treatment recommendation.
